Tae Life Sciences & Stella Pharma Announce BPA Strategic Agreement
TAE Life Sciences (TLS), a prominent developer of boron neutron capture therapy (BNCT) technology and related boron target drugs,...
Diamedica Doses First Patient in DM199 Preeclampsia Trial
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has initiated its Phase 2 investigator-sponsored trial for DM199, a potential preeclampsia...
Navigating Challenges in Sexual Health Innovation with Morari Medical
In this interview, we speak with Jeff Bennett, CEO of Morari Medical, about the challenges and strategies in developing...
Transforming Cardiac Imaging with AI: An Interview with UltraSight Davidi Vortman
In this interview, we speak with Davidi Vortman, CEO of UltraSight, about their innovative AI-driven ultrasound technology and how...
Mass General Brigham on Enhancing Clinical Trials: The Critical Role of Study Sites in Protocol Design
The design of a study’s protocol is pivotal to its success in clinical trials, and engaging study sites early...
GenSight Submits Lumevoq® Dossier to ANSM for Early Access Program Restart
GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French medicines safety agency...
Carmat’s Aeson® Artificial Heart Revolutionizes Transplants in Europe
CARMAT’s Aeson® artificial heart has seen increased adoption as a European bridge-to-transplant solution. By the end of October 2024,...
How GDPR Drives Trust in Patient-Centric Trials
In recent years, patient-centric trial designs have emerged as a transformative approach in clinical research, placing patients at the...
Quince Therapeutics Unveils Promising Attest Trial Safety Data at CNS Meeting
Quince Therapeutics, a late-stage biotechnology company, announced safety data from its Phase 3 ATTeST clinical trial at the 53rd...
Neurogene Reports Positive Interim Data from NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. announced positive interim clinical data from its Phase 1/2 open-label trial of NGN-401 gene therapy for Rett...